RAPT THERAPEUTICS, INC. (RAPT) News

RAPT THERAPEUTICS, INC. (RAPT): $21.68

0.27 (+1.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RAPT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 403

in industry

Filter RAPT News Items

RAPT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RAPT News Highlights

  • RAPT's 30 day story count now stands at 3.
  • Over the past 16 days, the trend for RAPT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • FOLD are the most mentioned tickers in articles about RAPT.

Latest RAPT News From Around the Web

Below are the latest news stories about RAPT Therapeutics Inc that investors may wish to consider to help them evaluate RAPT as an investment opportunity.

Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -107.14% and 0.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

RAPT Therapeutics to Participate in the 11th Annual SVB Leerink Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at the 11th Annual SVB Leerink Healthcare Conference on Wedne

Yahoo | February 9, 2022

State Board Of Administration Of Florida Retiremen Buys Canadian Pacific Railway, VMware Inc, ...

Investment company State Board Of Administration Of Florida Retiremen (Current Portfolio) buys Canadian Pacific Railway, VMware Inc, Coterra Energy Inc, Realty Income Corp, Clarivate PLC, sells , , , , during the 3-months ended 2021Q4, according to the most recent filings of the investment company, State Board Of Administration Of Florida Retiremen.

Yahoo | February 8, 2022

RAPT crashes ahead of presentation at J.P. Morgan Conference (NASDAQ:RAPT)

RAPT Therapeutics <> has recorded its biggest intraday loss since November 2020 on below-average volume as the clinical-stage biotech prepares for a presentation at a major…

Seeking Alpha | January 10, 2022

RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 9:00 a.

Yahoo | January 4, 2022

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Insider Sells $81,739.36 in Stock

RAPT Therapeutics, Inc. (NASDAQ:RAPT) insider Dirk G. Brockstedt sold 2,647 shares of the businesss stock in a transaction dated Friday, December 10th. The shares were sold at an average price of $30.88, for a total value of $81,739.36. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. []

Dakota Financial News | December 16, 2021

RAPT Therapeutics (NASDAQ:RAPT) Earns Overweight Rating from Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. initiated coverage on shares of RAPT Therapeutics (NASDAQ:RAPT) in a research note published on Thursday morning, Price Targets.com reports. The firm issued an overweight rating and a $61.00 target price on the stock. A number of other equities research analysts have also recently commented on the stock. Zacks Investment Research upgraded []

Dakota Financial News | December 12, 2021

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Insider Sells $94,507.12 in Stock

RAPT Therapeutics, Inc. (NASDAQ:RAPT) insider Dirk G. Brockstedt sold 2,648 shares of the stock in a transaction dated Thursday, November 11th. The shares were sold at an average price of $35.69, for a total transaction of $94,507.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at []

Transcript Daily | December 10, 2021

RAPT Therapeutics (NASDAQ:RAPT) Now Covered by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. began coverage on shares of RAPT Therapeutics (NASDAQ:RAPT) in a research report report published on Thursday, Analyst Price Targets reports. The brokerage issued an overweight rating and a $61.00 price objective on the stock. Other equities research analysts also recently issued reports about the company. SVB Leerink reaffirmed a buy rating […]

Transcript Daily | December 10, 2021

Analysts Offer Insights on Healthcare Companies: Apyx Medical (APYX), SCYNEXIS (SCYX) and RAPT Therapeutics (RAPT)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Apyx Medical (APYX – Research Report), SCYNEXIS (SCYX – Research Report) and RAPT Therapeutics (RAPT – Research Report) with bullish sentiments. Apyx Medical (APYX) In a report released today, Kyle Bauser from Colliers Securities reiterated a Buy rating on Apyx Medical, with a price target of $20.00. The company's shares closed last Wednesday at $14.19. According to TipRanks.com, Bauser is a 4-star analyst with an average return of -7.6% and a 24.1% success rate.

Brian Anderson on TipRanks | December 9, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4467 seconds.